Dear colleagues, we inform you about the inclusion of a new indication - attention deficit syndrome with hyperactivity (ADHG) in children aged 6 to 12 years, including hyperactivity, impaired attention, impulsivity - in the instructions for the medical use of the drug Mexidol ® , tablets covered with a film shell, 125 mg .
According to the conducted double-centered, randomized, placebo-controlled in three parallel groups, clinical research on assessing the effectiveness of the drug Mexidol ® in the treatment of ADHD in children ( mega ), Mexidol ® reliably improves the condition of such children and reduces the manifestations of SDVG symptoms by 29%: It helps to increase the concentration of attention and the ability to concentrate, increase perseverance, reduce signs of hyperactivity and reduce impulsivity, which leads to an improvement in the education and social adaptation of children. In addition, the study showed a high security profile of the drug Mexidol, comparable to placebo.
